Connection

Michael Hallek to Molecular Targeted Therapy

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Molecular Targeted Therapy.
Michael Hallek
Connection Strength
0.508
Molecular Targeted Therapy
  1. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
    View in: PubMed
    Score: 0.366
  2. Emerging therapies for refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Feb; 56(2):285-92.
    View in: PubMed
    Score: 0.071
  3. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019 11; 104(11):2144-2154.
    View in: PubMed
    Score: 0.026
  4. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 12; 58:7-13.
    View in: PubMed
    Score: 0.024
  5. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 09 21; 130(12):1477-1480.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.